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Background: Endocrinologic abnormalities are a common co-morbidity in patients with optic nerve hypoplasia
(ONH), however the impact on puberty is unknown. The purpose of this study was to examine rates of endocrine
dysfunction and pubertal disturbances in a pediatric population of ONH.
Methods: A retrospective chart review was conducted on a cohort of children with ONH between January 2005
and March 2013. Endocrine dysfunction was determined based on laboratory evidence of hormone deficiency or
hormone replacement. Pubertal disturbances were characterized based on presence of micropenis, tanner staging,
menarche and hormone replacement. Pituitary abnormalities were classified using MRI findings. Descriptive statistics
were used, and comparisons between groups were performed using the chi-square test.
Results: During the study period, 101 patients underwent an endocrine evaluation (median age: 2.3 years [0.76 – 6.5]).
Hypopituitarism was present in 73% of patients with growth hormone deficiency (56%) and hypothyroidism (54%)
being the most common. Pubertal disturbances (n = 19) were common; micropenis in 31% (13/42) of males and 2%
with precocious puberty. Half of adolescents (n = 4/8) were diagnosed with gonadotropin deficiency. Patients with MRI
pituitary abnormalities were more likely to have endocrine dysfunction than those without (p = 0.004). The sensitivity
and specificity of MRI pituitary abnormalities for hypopituitarism was 54% and 92%, respectively.
Conclusions: A significant proportion of children with ONH have endocrine dysfunction. The high frequency of
pubertal disturbances in this study emphasizes the need for long-term monitoring of developing endocrinopathy.
While pituitary gland abnormalities are a good predictor of endocrine dysfunction, a normal pituitary gland does not
rule out endocrinopathy.
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Optic nerve hypoplasia (ONH) is a congenital malformation
that manifests as a spectrum disorder of visual impairment
with cerebral malformations, hypopituitarism and develop-
mental delay [1-3]. The prevalence of ONH is estimated at
1.73 per 10,000 children [4]. In the United States, ONH is a
leading cause of legal blindness in children age 3 years or
younger [5].
One of the most widely studied and recognized clinical
association of ONH is hypopituitarism, ranging from 6%
to 82% depending on the study design and patient
sampling [6-13]. In a prospective clinical registry of young
children with ONH, endocrinopathy affected 60-79% of* Correspondence: ooatman@phoenixchildrens.com
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unless otherwise stated.children by age five years [10-12]. The most common
hormone deficiency is growth hormone (GH) followed
by central hypothyroidism [9,11]. Clinical management
guidelines recommend long-term follow-up given reports
of evolving central hypothyroidism [14], subclinical
GH deficiency (paradoxical “growth without GH”) [10],
and the association of untreated hypopituitarism with
developmental delay and even death [12-15].
Pubertal disturbances are an understudied endocrinopa-
thy in children with ONH. There have been more than a
dozen cases of precocious puberty and/or gonadotropin
deficiency reported [16-18] implicating pubertal disturbances
as an additional risk. The unknown prevalence is likely
due to past research being limited to prepubertal cases
and absence of long-term follow-up into adolescence.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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examine the prevalence of hypopituitarism in a clinical
cohort of patients with ONH age 18 years and younger.
The results of this study provide additional evidence of
endocrinopathy risk throughout the age continuum in
children with ONH.
Methods
A retrospective study of patients with ONH was con-
ducted on all patients evaluated in an endocrinology
clinic at Phoenix Children’s Hospital between January
2005 and March 2013. All patients with a documented
diagnosis of ONH or septo-optic dysplasia were included.
Data abstracted from the medical record included patient
demographics, anthropometric measures (height, weight,
weight for length, body mass index), hormone test re-
sults, medications, and neuroradiographic findings from
magnetic resonance imaging (MRI). Self-identified race
was obtained based on medical record documentation
with the following classifications: Caucasian, Hispanic,
Native American, African-American, or other.
Subjects’ endocrine status was determined based on
laboratory evidence of a hormone deficiency or
current hormone replacement prior to clinic presentation.
Laboratory test results were obtained when available.
Patients were classified as GH deficient (GHD) based
on subnormal growth factors [insulin-like growth
factor-1 (IGF-1) and insulin-like growth factor binding
protein-3 (IGFBP3)] levels below reference ranges, failed
GH stimulation test with peak GH level < 10 ng/mL (using
arginine, clonidine, or glucagon as stimulation agents), or
hormone replacement. Central hypothyroidism was
determined based on free thyroxine (T4) levels below
reference ranges or hormone replacement. Adrenal insuffi-
ciency was determined based on fasting morning cortisol
below reference ranges, subnormal cortisol response
to adrenocorticotropic hormone (ACTH) stimulation
test (peak < 18 μg/dL) or hormone replacement. Patients
treated with desmopressin were classified as having
diabetes insipidus.
Pubertal disturbance was ascertained based on pres-
ence of micropenis (stretched penile length 2.5 standard
deviations below the mean), advanced or delayed tanner
staging, premature or absence of menarche, and/or
the need for testosterone or estrogen replacement.
Precocious puberty was determined based on presence
of secondary sexual characteristics prior to age eight
in females and age nine in males with evidence of pubertal
levels of gonadotropins, testosterone or estradiol, or
history of treatment with a gonadotropin-releasing
hormone (GnRH) agonist. Gonadotropin deficiency was
based on absence of menarche in females by age 15 or no
secondary sexual characteristics by age 13 in females and
14 in males.Data analysis
A descriptive analysis was conducted using Stata 13.0
(College Station, TX). Clinical and demographic findings
were summarized using medians (interquartile range)
and proportions. Comparisons between groups were
performed using the chi-square test for categorical




Data from 101 patients with ONH were available for
review. Table 1 presents the patient characteristics for
the study sample. The median age at the time of
clinic presentation was 2.3 years (0.7, 6.5). For the
overall cohort, the median height and weight z-scores
were −1.3 (−2.2, −0.3) and −0.7 (−1.7, −0.6), respectively.
Among subjects less than age two years (n = 47), the
median weight for length z-score was 0.6 (−0.6, 1.3). The
median body mass index (BMI) z-score, measurable in
those age two years or older (n = 50), was 0.7 (−0.3, 1.5).
Endocrine evaluation
Seventy-two percent (n = 73/101) of patients had at least
one endocrinopathy (Table 1) and 57% (n = 58/101) had
multiple pituitary hormone deficiency (MPHD) (2 or
more hormone deficiencies). Among subjects with GHD
(62%), the median height SDS was −1.6 (−2.5, −0.7)
compared to −0.45 (−1.6, 0.2) deemed GH sufficient
(p = 0.001). There were three cases of isolated
hypothyroidism, one case of isolated adrenal insufficiency
and one case of isolated gonadotropin deficiency. All cases
of diabetes insipidus (n = 28) co-existed with another
pituitary deficiency: GHD (71%), hypothyroidism (86%)
and adrenal insufficiency (82%).
At the initial endocrine visit [median age 2.3 years
(0.7, 6.5)], thyroid hormone levels were measured in 82%
(TSH: 82% and free T4: 98%), cortisol in 86%, and GH
surrogates (IGF-1 and/or IGFBP3) in 89%. Seventy-one
percent underwent serial free T4 testing after initial normal
thyroid tests. Nearly all patients (>80%) underwent follow
up testing for cortisol (repeat cortisol and/or cortisol
provocative testing: 86%) and GH (repeat IGF’s and/or GH
stimulation test: 83%). Pubertal hormone levels, in those
younger than age 6 months or at pubertal age (n = 41),
were measured in 42% for luteinizing hormone (LH)/
follicle-stimulating hormone (FSH) and 35% for testosterone
or estradiol.
Pubertal disturbances
There were 15 subjects with a pubertal disturbance prior
to pubertal age: two with precocious puberty and 13
(out of 42 males) with micropenis. Among males with
micropenis, two were followed into a pubertal age; both















Native American 12.9 13/101
Other 7 7/101




Not documented 13.9 14/101
Brain Malformationsc
Pituitary abnormalities 44.1 26/59
Absence of septum pellucidum 46.8 36/77
Corpus callosum hypoplasia 34.7 25/72
Cortical dysplasia 16.9 14/83
Schizencephaly 10.9 9/83
Hydrocephalus 8.4 7/83
Arachnoid cyst 6.0 5/83
Endocrinopathiesd
Any endocrinopathy 72.3 73/101
GH deficiency 62.0 57/92
Hypothyroidism 54.0 54/100
Adrenal insufficiency 51.1 47/92
Diabetes insipidus 27.7 28/101
aSome insurance plans only allow the primary pediatrician to order referrals.
bBased on documentation in the medical record.
cTotal number of subjects varies based on available MRI reports.
dTotal number of subjects varies based on available lab results.
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association between presence of micropenis and MPHD
(p = 0.72).
Among subjects at a pubertal age (n = 26), 24 had a
Tanner stage evaluation. Nine females (out of 15) were
Tanner II-V and six were Tanner I (age 8–9 years old). Five
males (out of 9) were Tanner II-V and four were Tanner I
(age 10–16 years old).There were 15 girls at potential menarchal age (≥9 years);
40% had spontaneous menarche (median age of onset
12 years; 10.5 – 13 years). In those with MPHD, 66%
(n = 4/6) had spontaneous menarche by age 15.
Eight patients (two males and six females) were followed
into an age when gonadotropin deficiency could be
assessed, with 50% (n = 4/8) being diagnosed. One male
with MPHD was diagnosed with gonadotropin deficiency
based on a Tanner I stage at age 16 years with low FSH,
LH, and testosterone levels (started testosterone therapy).
Three females were diagnosed with gonadotropin deficiency
and all had MPHD. One female had menarche at age 14,
but subsequently developed irregular periods in her late
teen years; she had low estrogen and LH / FSH levels and
began estrogen therapy. A second female did not achieve
menarche by 15 with only Tanner II breast development
and no pubic hair (started estrogen therapy). A third female
failed to achieve menarche by age 15 years with Tanner II
pubic hair, no breast development, and low LH/FSH levels
(lost to follow-up).
Brain malformations
Eighty-two patients underwent a MRI. Table 1 lists the
findings documented in the MRI report. An absent
septum pellucidum, present in 47%, was not associated
with hypopituitarism (75% versus 76%; p = 0.951). The
pituitary gland status, documented for 59 subjects, was
abnormal in 25 cases. The frequency of pituitary gland
abnormalities was similar for those with (54%) and without
(63%) the septum pellucidum (p = 0.530). Pituitary gland
abnormalities included an absent or hypoplastic pituitary
gland in (n = 18), ectopic posterior pituitary (n = 13), absent
or truncated stalk (n = 13), and absent posterior pituitary
bright spot (n = 4). An ectopic posterior pituitary gland
(stalk present in nine patients) was associated with DI in
three cases (stalk present in two). A non-visualized
posterior pituitary bright spot was an isolated finding
for three subjects (no DI), and associated with an absent
stalk in one subject (no DI).
Hypopituitarism manifested in 96% of patients with a
reported pituitary gland malformation, compared to 64%
of those with an intact pituitary gland (p = 0.004). The
sensitivity and specificity of MRI pituitary abnormalities
for hypopituitarism was 54% and 92%, respectively. The
predictive values were 96% (positive) and 36% (negative).
Discussion
The high prevalence of hypopituitarism in our cohort
confirms previous reports of endocrinopathy in a majority
of cases of ONH [2,9-12]. Overall, pubertal disturbances
affected one-fifth of the cohort.
Pubertal disturbances in association with ONH was first
described in 1978 in a female with precocious puberty
[16]. Since then there have been 11 reported cases of
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present study, precocious puberty affected two patients
(2%). The exact mechanism of precocious puberty in ONH
is unknown. Huseman et al. [16] originally postulated that
precocious puberty may be due to “decreased inhibitory
inputs from higher centers of the central nervous system.”
Since ONH is a neurodevelopmental abnormality, it is
reasonable to assume there could be a disruption in
inhibitory inputs or an increase in excitatory inputs to the
hypothalamic GnRH neurons, leading to dysregulated
GnRH secretion and precocious puberty. Hydrocephalus
and arachnoid cysts, cerebral developmental abnormalities
known to cause precocious puberty [19], were seen in
seven and five patients in this study. However, neither
patient with precocious puberty had these abnormalities.
Future studies should examine the association of precocious
puberty with these cerebral abnormalities.
Pubertal disturbances are linked to a disruption of the
hypothalamic-pituitary-gonadal (HPG) axis. Ascertainment
of pubertal hormone deficiencies is complicated by the
limited time periods for measurement of pubertal hormone
levels. Infants undergo a ‘mini-puberty’ during the first six
months of life. If this early window is missed, pubertal
hormones cannot be measured until an age when
secondary sexual characteristics may occur naturally
(≥8 in females, ≥9 in males). In males, micropenis is the
most commonly reported sign of pubertal disturbances in
ONH, present in one-third of males in this cohort. Since
micropenis is not present in all cases of gonadotropin
deficiency, future research should include follow up of
male patients with ONH into adolescence to establish a
diagnosis of gonadotropin deficiency.
Researchers posit gonadotropin deficiency is less
common in patients with ONH and MPHD compared to
other causes of MPHD, which may reflect migration of
GnRH neurons from the nasal mucosa to the hypothalamus
after the proposed insult in ONH [18,24]. In ONH, the
pituitary gland is structurally intact in the majority of cases
[6,11,13]. Formation of the anterior pituitary gland precedesTable 2 Pubertal disturbances in ONH
Study Sample size Precocious puberty ca
Huseman, 1978 [16] 5 1
Margalith, 1985 [20] 17 1
Hanna, 1989 [17] 13 1
Siatkowski, 1997 [21] 35 1
Nanduri, 1999 [18] 25 -
Phillips, 2001 [6] 67 -
Reidl, 2002 [22] 25 -
Birkebaek, 2003 [7] 55 6
Haddad, 2005 [9] 56 1
Mohney, 2013 [23] 19 1development of the posterior pituitary, stalk and hypothal-
amus at seven weeks. Hypothalamic releasing factors
are present around 10–14 weeks, with a functional
hypothalamic-hypophyseal portal system by the 11th
week. This complex network allows communication of
hypothalamic releasing factors to their respective pituitary
somatotrophs, thyrotrophs, corticotrophs, and gonadotrophs,
stimulating the release of anterior pituitary hormones.
Unlike other hypothalamic releasing factor neurons,
GnRH neurons migrate from the olfactory placode to the
hypothalamus by 10–14 weeks [25,26]. It is reasonable to
assume that an insult to the hypothalamic-pituitary axis
prior to this time period may result in preserved GnRH
function.
Gonadotropin deficiency has been reported in multiple
patients with ONH (Table 2), yet a prevalence has been
difficult to establish as very few patients are followed into
pubertal age. Nanduri et al. [18] reported gonadotropin
deficiency in 42% of children with ONH that reached
pubertal age. Our study found gonadotropin deficiency in
50% of those at pubertal age. In other hypothalamic-pituitary
diseases (without ONH), gonadotropin deficiency is com-
mon: 96% in child-onset craniopharyngioma and 86% in
child-onset hypopituitarism (mostly idiopathic) [27].
The lower prevalence of gonadotropin deficiency in
ONH may support the theory of an intact HPG axis
due to a later GnRH migration into the hypothalamus.
However, if this was entirely true, then no cases of
gonadotropin deficiency would be expected. A completely
functional HPG axis is needed for normal pubertal devel-
opment. Gonadotropin deficiency could be explained by
an insult to the pituitary gland itself, resulting in abnormal
gonadotroph development. Very few patients in our
study of pubertal age had MRI reports available, so
pituitary abnormalities could not be evaluated in relation
to gonadotropin deficiency.
Expert opinion recommendations encourage a thorough
and serial endocrine evaluation on all patients with ONH
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evolving hypopituitarism [1,14]. However, there is debate
about the use of imaging findings to direct endocrinologic
testing in patients with ONH [28]. Phillips et al. [6] and
Birkebaek et al. [7] were the first to suggest selective
screening for hypopituitarism in patients with pituitary
gland abnormalities. In some reports, the sensitivity and
specificity of pituitary abnormalities on MRI ranged from
85% to 96% and 57% to 100%, respectively [6,7,13]. A
prospective study of young children with ONH reported a
high specificity (100%) and a low sensitivity of 7% [10]. In
our cohort, pituitary gland abnormalities on MRI had a
sensitivity of 54% and specificity of 92%. The low negative
predictive value in the study by Ahmad et al. [10] (29%)
and our study (36%) indicates a structurally intact pituitary
gland is a poor predictor of normal endocrine function.
High negative predictive values reported in other studies
may reflect incomplete endocrine screening.
The HPG axis was evaluated in nearly half of our
patients less than 6 months old or at pubertal age.
Given our findings of a pubertal disturbance in 19%
of subjects and 50% of pubertal patients diagnosed
with gonadotropin deficiency, an evaluation of the HPG
axis should be performed in all patients with ONH.
There were several limitations in our study. Similar to
other reports using a single endocrine clinic cohort, our
study was subject to selection bias and differential
hormone testing. A complete endocrine evaluation
was not performed in all patients and may have resulted
in an underestimated prevalence of endocrinopathy.
Ascertainment of hypopituitarism relied on clinical docu-
mentation, rather than systematic testing and standardized
classification. For GHD, growth pattern data were not
available for many of the patients, which affected confirm-
ation of diagnosis in those on replacement therapy or with
no anthropometrics prior to initiating therapy. MRI
testing was performed at several institutions and imaging
centers. Variability in the interpretation of MRI pituitary
abnormalities between neuroradiologists may have led to
an under or over-reporting of pituitary abnormalities.
Conclusions
Among children with ONH, the prevalence of endocri-
nopathy is high including abnormalities in the HPG axis.
Practitioners should be aware of the potential for preco-
cious puberty throughout childhood and once patients
reach a pubertal age, pubertal progression should be
monitored annually. Evaluation of the HPG axis should
be performed when patients fail to initiate puberty by an
appropriate age (13 in females, 14 in males). Presence
of micropenis, failure to progress through puberty
normally, primary amenorrhea, or irregular menses would
also warrant evaluation. Due to conflicting negative
predictive values in evaluating MRI pituitary abnormalitiesin association with endocrinopathy, a normal pituitary
gland on MRI should not exclude patients with ONH
from an endocrine evaluation.
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